Cargando…

Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma Patients

Background: The use of (18)F-2-Fluor-2-desoxy-D-glucose Positron Emission Tomography/Computed Tomography FDG-PET/CT in clinical routine for staging, treatment response monitoring and post treatment surveillance in metastatic melanoma patients has noticeably increased due to significant improvement o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kudura, Ken, Dimitriou, Florentia, Mihic-Probst, Daniela, Muehlematter, Urs J., Kutzker, Tim, Basler, Lucas, Förster, Robert, Dummer, Reinhard, Mangana, Joanna, Husmann, Lars, Burger, Irene A., Kreissl, Michael Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156636/
https://www.ncbi.nlm.nih.gov/pubmed/34063555
http://dx.doi.org/10.3390/diagnostics11050883
_version_ 1783699492650876928
author Kudura, Ken
Dimitriou, Florentia
Mihic-Probst, Daniela
Muehlematter, Urs J.
Kutzker, Tim
Basler, Lucas
Förster, Robert
Dummer, Reinhard
Mangana, Joanna
Husmann, Lars
Burger, Irene A.
Kreissl, Michael Christoph
author_facet Kudura, Ken
Dimitriou, Florentia
Mihic-Probst, Daniela
Muehlematter, Urs J.
Kutzker, Tim
Basler, Lucas
Förster, Robert
Dummer, Reinhard
Mangana, Joanna
Husmann, Lars
Burger, Irene A.
Kreissl, Michael Christoph
author_sort Kudura, Ken
collection PubMed
description Background: The use of (18)F-2-Fluor-2-desoxy-D-glucose Positron Emission Tomography/Computed Tomography FDG-PET/CT in clinical routine for staging, treatment response monitoring and post treatment surveillance in metastatic melanoma patients has noticeably increased due to significant improvement of the overall survival rate in melanoma patients. However, determining the dignity of the findings with increased metabolic activity on FDG-PET/CT can be sometimes challenging and may need further investigation. Purpose: We aimed to investigate the malignancy rate of indeterminate findings on FDG-PET/CT in metastatic cutaneous melanoma patients. Methods: This single-center retrospective study included cutaneous melanoma patients who underwent FDG-PET/CT in clinical routine between 2015 and 2017 with findings reported as indeterminate and therefore requiring further evaluation. The dignity of the included findings was determined by subsequent imaging and, if required, additional histopathology. The impact of the outcome on the clinical management was also reported. Results: A total of 842 FDG-PET/CT reports of 244 metastatic cutaneous melanoma patients were reviewed. Sixty indeterminate findings were included. Almost half of all indeterminate findings were lymph nodes, lung nodules and cerebral lesions. In total, 43.3% of all included findings proved to be malignant. 81% of all malignant lesions were metastases of cutaneous melanoma, while 19% of all malignant lesions could be attributed to other primary malignancies, such as lung, breast, thyroid and colorectal cancers. Malignant findings influenced clinical management in 60% of the cases. Conclusion: Indeterminate findings on FDG-PET/CT in metastatic cutaneous melanoma patients should be further investigated. Almost one out of every two indeterminate findings on FDG-PET/CT is malignant. The majority of the findings are melanoma manifestations, however, in a significant percentage, other primary tumors are found. Upon verification, patient management is changed in most cases.
format Online
Article
Text
id pubmed-8156636
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81566362021-05-28 Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma Patients Kudura, Ken Dimitriou, Florentia Mihic-Probst, Daniela Muehlematter, Urs J. Kutzker, Tim Basler, Lucas Förster, Robert Dummer, Reinhard Mangana, Joanna Husmann, Lars Burger, Irene A. Kreissl, Michael Christoph Diagnostics (Basel) Article Background: The use of (18)F-2-Fluor-2-desoxy-D-glucose Positron Emission Tomography/Computed Tomography FDG-PET/CT in clinical routine for staging, treatment response monitoring and post treatment surveillance in metastatic melanoma patients has noticeably increased due to significant improvement of the overall survival rate in melanoma patients. However, determining the dignity of the findings with increased metabolic activity on FDG-PET/CT can be sometimes challenging and may need further investigation. Purpose: We aimed to investigate the malignancy rate of indeterminate findings on FDG-PET/CT in metastatic cutaneous melanoma patients. Methods: This single-center retrospective study included cutaneous melanoma patients who underwent FDG-PET/CT in clinical routine between 2015 and 2017 with findings reported as indeterminate and therefore requiring further evaluation. The dignity of the included findings was determined by subsequent imaging and, if required, additional histopathology. The impact of the outcome on the clinical management was also reported. Results: A total of 842 FDG-PET/CT reports of 244 metastatic cutaneous melanoma patients were reviewed. Sixty indeterminate findings were included. Almost half of all indeterminate findings were lymph nodes, lung nodules and cerebral lesions. In total, 43.3% of all included findings proved to be malignant. 81% of all malignant lesions were metastases of cutaneous melanoma, while 19% of all malignant lesions could be attributed to other primary malignancies, such as lung, breast, thyroid and colorectal cancers. Malignant findings influenced clinical management in 60% of the cases. Conclusion: Indeterminate findings on FDG-PET/CT in metastatic cutaneous melanoma patients should be further investigated. Almost one out of every two indeterminate findings on FDG-PET/CT is malignant. The majority of the findings are melanoma manifestations, however, in a significant percentage, other primary tumors are found. Upon verification, patient management is changed in most cases. MDPI 2021-05-15 /pmc/articles/PMC8156636/ /pubmed/34063555 http://dx.doi.org/10.3390/diagnostics11050883 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kudura, Ken
Dimitriou, Florentia
Mihic-Probst, Daniela
Muehlematter, Urs J.
Kutzker, Tim
Basler, Lucas
Förster, Robert
Dummer, Reinhard
Mangana, Joanna
Husmann, Lars
Burger, Irene A.
Kreissl, Michael Christoph
Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma Patients
title Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma Patients
title_full Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma Patients
title_fullStr Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma Patients
title_full_unstemmed Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma Patients
title_short Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma Patients
title_sort malignancy rate of indeterminate findings on fdg-pet/ct in cutaneous melanoma patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156636/
https://www.ncbi.nlm.nih.gov/pubmed/34063555
http://dx.doi.org/10.3390/diagnostics11050883
work_keys_str_mv AT kuduraken malignancyrateofindeterminatefindingsonfdgpetctincutaneousmelanomapatients
AT dimitriouflorentia malignancyrateofindeterminatefindingsonfdgpetctincutaneousmelanomapatients
AT mihicprobstdaniela malignancyrateofindeterminatefindingsonfdgpetctincutaneousmelanomapatients
AT muehlematterursj malignancyrateofindeterminatefindingsonfdgpetctincutaneousmelanomapatients
AT kutzkertim malignancyrateofindeterminatefindingsonfdgpetctincutaneousmelanomapatients
AT baslerlucas malignancyrateofindeterminatefindingsonfdgpetctincutaneousmelanomapatients
AT forsterrobert malignancyrateofindeterminatefindingsonfdgpetctincutaneousmelanomapatients
AT dummerreinhard malignancyrateofindeterminatefindingsonfdgpetctincutaneousmelanomapatients
AT manganajoanna malignancyrateofindeterminatefindingsonfdgpetctincutaneousmelanomapatients
AT husmannlars malignancyrateofindeterminatefindingsonfdgpetctincutaneousmelanomapatients
AT burgerirenea malignancyrateofindeterminatefindingsonfdgpetctincutaneousmelanomapatients
AT kreisslmichaelchristoph malignancyrateofindeterminatefindingsonfdgpetctincutaneousmelanomapatients